AbCellera Biologics (ABCL) Net Income towards Common Stockholders (2020 - 2023)
Historic Net Income towards Common Stockholders for AbCellera Biologics (ABCL) over the last 4 years, with Q4 2023 value amounting to -$47.2 million.
- AbCellera Biologics' Net Income towards Common Stockholders fell 5772.92% to -$47.2 million in Q4 2023 from the same period last year, while for Sep 2024 it was -$47.2 million, marking a year-over-year increase of 6348.95%. This contributed to the annual value of -$162.9 million for FY2024, which is 1124.26% down from last year.
- AbCellera Biologics' Net Income towards Common Stockholders amounted to -$47.2 million in Q4 2023, which was down 5772.92% from -$28.6 million recorded in Q3 2023.
- Over the past 5 years, AbCellera Biologics' Net Income towards Common Stockholders peaked at $168.6 million during Q1 2022, and registered a low of -$47.2 million during Q4 2023.
- In the last 4 years, AbCellera Biologics' Net Income towards Common Stockholders had a median value of -$2.5 million in 2020 and averaged $17.8 million.
- Within the past 5 years, the most significant YoY rise in AbCellera Biologics' Net Income towards Common Stockholders was 570062.11% (2021), while the steepest drop was 69391.01% (2021).
- Quarter analysis of 4 years shows AbCellera Biologics' Net Income towards Common Stockholders stood at $117.0 million in 2020, then crashed by 48.76% to $59.9 million in 2021, then tumbled by 149.86% to -$29.9 million in 2022, then plummeted by 57.73% to -$47.2 million in 2023.
- Its Net Income towards Common Stockholders was -$47.2 million in Q4 2023, compared to -$28.6 million in Q3 2023 and -$30.5 million in Q2 2023.